138 related articles for article (PubMed ID: 29362422)
1. A caspase-2-RFXANK interaction and its implication for MHC class II expression.
Forsberg J; Li X; Akpinar B; Salvatori R; Ott M; Zhivotovsky B; Olsson M
Cell Death Dis; 2018 Jan; 9(2):80. PubMed ID: 29362422
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
3. Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases.
Wang AH; Grégoire S; Zika E; Xiao L; Li CS; Li H; Wright KL; Ting JP; Yang XJ
J Biol Chem; 2005 Aug; 280(32):29117-27. PubMed ID: 15964851
[TBL] [Abstract][Full Text] [Related]
4. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
5. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
[TBL] [Abstract][Full Text] [Related]
6. New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.
Krawczyk M; Masternak K; Zufferey M; Barras E; Reith W
Mol Cell Biol; 2005 Oct; 25(19):8607-18. PubMed ID: 16166641
[TBL] [Abstract][Full Text] [Related]
7. Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
Okada K; Hakata S; Terashima J; Gamou T; Habano W; Ozawa S
Oncol Rep; 2016 Oct; 36(4):1875-85. PubMed ID: 27509880
[TBL] [Abstract][Full Text] [Related]
8. Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK.
McKinsey TA; Kuwahara K; Bezprozvannaya S; Olson EN
Mol Biol Cell; 2006 Jan; 17(1):438-47. PubMed ID: 16236793
[TBL] [Abstract][Full Text] [Related]
9. A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review.
Cai YQ; Zhang H; Wang XZ; Xu C; Chao YQ; Shu Y; Tang LF
Open Forum Infect Dis; 2020 Aug; 7(8):ofaa314. PubMed ID: 32875002
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
11. MHC class I and II deficiencies.
Hanna S; Etzioni A
J Allergy Clin Immunol; 2014 Aug; 134(2):269-75. PubMed ID: 25001848
[TBL] [Abstract][Full Text] [Related]
12. Regulation of major histocompatibility (MHC) class II human leukocyte antigen-DR alpha gene expression in thyrocytes by single strand binding protein-1, a transcription factor that also regulates thyrotropin receptor and MHC class I gene expression.
Balducci-Silano PL; Suzuki K; Ohta M; Saito J; Ohmori M; Montani V; Napolitano G; Shong M; Taniguchi SI; Pietrarelli M; Lavaroni S; Mori A; Singer DS; Kohn LD
Endocrinology; 1998 May; 139(5):2300-13. PubMed ID: 9564838
[TBL] [Abstract][Full Text] [Related]
13. Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression.
Bhat KP; Truax AD; Brooks JK; Greer SF
Immunol Cell Biol; 2010; 88(8):807-16. PubMed ID: 20351748
[TBL] [Abstract][Full Text] [Related]
14. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.
Nekrep N; Geyer M; Jabrane-Ferrat N; Peterlin BM
Mol Cell Biol; 2001 Aug; 21(16):5566-76. PubMed ID: 11463838
[TBL] [Abstract][Full Text] [Related]
15. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
Goodwin BL; Xi H; Tejiram R; Eason DD; Ghosh N; Wright KL; Nagarajan U; Boss JM; Blanck G
Cell Growth Differ; 2001 Jun; 12(6):327-35. PubMed ID: 11432807
[TBL] [Abstract][Full Text] [Related]
16. [Research progress on regulation of class II MHC expression].
Sun QH; Peng JP
Sheng Li Ke Xue Jin Zhan; 2004 Jan; 35(1):25-9. PubMed ID: 15127593
[TBL] [Abstract][Full Text] [Related]
17. Caspase-2 associates with FAN through direct interaction and overlapping functionality.
Forsberg J; Li X; Zamaraev AV; Panaretakis T; Zhivotovsky B; Olsson M
Biochem Biophys Res Commun; 2018 May; 499(4):822-828. PubMed ID: 29621545
[TBL] [Abstract][Full Text] [Related]
18. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
19. Absence of MHC class II antigen expression in trophoblast cells results from a lack of class II transactivator (CIITA) gene expression.
Murphy SP; Tomasi TB
Mol Reprod Dev; 1998 Sep; 51(1):1-12. PubMed ID: 9712312
[TBL] [Abstract][Full Text] [Related]
20. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.
Prod'homme T; Dekel B; Barbieri G; Lisowska-Grospierre B; Katz R; Charron D; Alcaide-Loridan C; Pollack S
Immunogenetics; 2003 Nov; 55(8):530-9. PubMed ID: 14574520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]